Aging is a gradual and irreversible pathophysiological process. It presents with declines in
tissue and cell functions and significant increases in the risks of various aging-related …

Inhibition of the protein kinase mechanistic target of rapamycin (mTOR) with the Food and
Drug Administration (FDA)-approved therapeutic rapamycin promotes health and longevity …

In 2009, rapamycin was reported to increase the lifespan of mice when implemented later in
life. This observation resulted in a sea-change in how researchers viewed aging. This was …

Macroautophagy/autophagy is primarily accountable for the degradation of damaged
organelles and toxic macromolecules in the cells. Regarding the essential function of …

Age‐related diseases represent some of the largest unmet clinical needs of our time. While
treatment of specific disease‐related signs has had some success (for example, the effect of …

With research progress on longevity, we have gradually recognized that cardiac aging
causes changes in heart structure and function, including progressive myocardial …

Aging is the main risk factor for Alzheimer's disease (AD) and other neurodegenerative
pathologies, but the molecular and cellular changes underlying pathological aging of the …

Current concepts regarding the biology of aging are primarily based on studies aimed at
identifying factors regulating lifespan. However, lifespan as a sole proxy measure for aging …

The mechanistic target of rapamycin (mTOR) integrates several intracellular and
extracellular signals involved in the regulation of anabolic and catabolic processes. mTOR …

Cellular senescence is a pivotal factor contributing to aging and the pathophysiology of age-
related diseases. Despite the presence of inflammation and abnormal immune system …